Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Author:

Muchtar Eli1ORCID,Dispenzieri Angela1ORCID,Wisniowski Brendan2,Palladini Giovanni34ORCID,Milani Paolo34ORCID,Merlini Giampaolo34ORCID,Schönland Stefan5ORCID,Veelken Kaya5,Hegenbart Ute5ORCID,Geyer Susan M.6,Kumar Shaji K.1ORCID,Kastritis Efstathios7ORCID,Dimopoulos Meletios A.7ORCID,Liedtke Michaela8ORCID,Witteles Ronald8,Sanchorawala Vaishali9ORCID,Szalat Raphael9,Landau Heather10ORCID,Petrlik Erica10,Lentzsch Suzanne11ORCID,Coltoff Alexander11,Bladé Joan12,Cibeira Maria Teresa12,Cohen Oliver2,Foard Darren2,Wechalekar Ashutosh2,Gertz Morie A.1ORCID

Affiliation:

1. Division of Hematology, Mayo Clinic, Rochester, MN

2. National Amyloidosis Centre, University College London, Royal Free Hospital Campus, London, United Kingdom

3. Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

4. Department of Molecular Medicine, University of Pavia, Pavia, Italy

5. Medical Department V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany

6. Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN

7. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

8. Stanford Amyloid Center, Stanford University School of Medicine, Stanford, CA

9. Section of Hematology and Oncology, Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, MA

10. Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

11. Division of Hematology/Oncology, Columbia University Medical Center, New York, NY

12. Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain

Abstract

PURPOSE Binary cardiac response assessment using cardiac biomarkers is prognostic in light chain amyloidosis. Previous studies suggested four-level cardiac responses using N-terminal prohormone of brain natiuretic peptide improves prognostic prediction. This study was designed to validate graded cardiac response criteria using N-terminal prohormone of brain natiuretic peptide/brain natiuretic peptide. PATIENTS AND METHODS This retrospective, multicenter study included patients with light chain amyloidosis who achieved at least a hematologic partial response (PR) and were evaluable for cardiac response. Four response criteria were tested on the basis of natriuretic peptide response depth: cardiac complete response (CarCR), cardiac very good partial response (CarVGPR), cardiac PR (CarPR), and cardiac no response (CarNR). Response was classified as best response and at fixed time points (6, 12, and 24 months from therapy initiation). The study primary outcome was overall survival. RESULTS 651 patients were included. Best CarCR, CarVGPR, CarPR, and CarNR were achieved in 16%, 26.4%, 22.9%, and 34.7% of patients, respectively. Patients in cardiac stage II were more likely to achieve CarCR than patients in cardiac stage IIIA and IIIB (22% v 13.5% v 3.2%; P < .001). A deeper cardiac response was associated with a longer survival (5-year overall survival 93%, 79%, 65%, and 33% for CarCR, CarVGPR, CarPR, and CarNR, respectively; P < .001). Fixed time-point analyses and time-varying covariates Cox regression analysis, to minimize survivorship bias, affirmed the independent survival advantage of deeper cardiac responses. Four-level response performed better than two-level response as early as 12 months from therapy initiation. CONCLUSION Graded cardiac response criteria allow better assessment of cardiac improvement compared with the traditional binary response system. The study re-emphasizes the importance of early diagnosis, which increases the likelihood of deep cardiac responses.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3